EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects

Pengkai Wang, Yuan Li, Bing Xu, Ping Zhang, Chang Cui, Xin Li

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1507 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Pengkai Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Fluticasone. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluticasone propionate nasal spray is widely regarded as a first‐line therapy for allergic rhinitis. To establish bioequivalence between the test and reference products of fluticasone propionate nasal spray, an open‐label, randomized, single‐dose, and 2‐sequence crossover study was conducted on 84 healthy Chinese subjects under fasting conditions to determine the pharmacokinetic bioequivalence of the 2 products. Following a single‐dose administration (200 µg) of fluticasone propionate nasal spray, pharmacokinetic parameters, including maximum plasma concentration, area under the concentration–time curve from administration to the last measurable concentration, and area under the concentration–time curve from administration to infinity, exhibited similarity between the 2 products, with 90% confidence intervals for the test/reference ratios falling within the bioequivalence range of 80%‐125%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluticasoneAdultFemaleHumansMaleYoung AdultAdministration, IntranasalArea Under CurveChinaCross-Over StudiesHealthy VolunteersNasal SpraysTherapeutic EquivalencyEast Asian People

Stichwörter der Autor:innen

allergic rhinitisbioequivalencefluticasone propionatenasal spraypharmacokineticssafety

Substanzen

FluticasoneNasal Sprays

Autor:innen und Institutionen

  • Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
  • Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, People's Republic of China.
  • Shanghai Omni Pharmaceutical Co., Ltd, Shanghai, People's Republic of China.

Zitieren

APA

Wang, P., Li, Y., Xu, B., Zhang, P., Cui, C., & Li, X. (2025). Pharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1507

Vancouver

Wang P, Li Y, Xu B, Zhang P, Cui C, Li X. Pharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1507

BibTeX
@article{Wang2025,
  author = {Wang, Pengkai and Li, Yuan and Xu, Bing and Zhang, Ping and Cui, Chang and Li, Xin},
  title = {Pharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1507}
}
Kostenlos starten →